Can a new antibody calm the immune attack in CIDP?
NCT ID NCT05581199
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This trial is testing whether an experimental drug called batoclimab can help adults with active chronic inflammatory demyelinating polyneuropathy (CIDP), a condition where the immune system damages nerves, causing weakness and disability. Participants receive either batoclimab or a placebo for 12 weeks, followed by a withdrawal period to see if the drug prevents relapses. The study aims to see if batoclimab can reduce disability and improve quality of life for people with CIDP.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- batoclimab (an experimental antibody that blocks a protein to lower harmful immune activity)
- What this could lead to
- If successful, batoclimab could offer a new treatment option for CIDP, potentially reducing relapses and improving daily function for people with this nerve disorder.
- What could go wrong
- This is a phase 2b trial with a relatively small number of participants, so results may not be definitive. Batoclimab may not prove more effective than placebo, and it could carry risks such as infections or allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SIte Number - 8400
Constanța, 900591, Romania
-
Site Number - 1602
Kansas City, Kansas, 66160, United States
-
Site Number - 1603
Scottsdale, Arizona, 85028, United States
-
Site Number - 1604
St. Petersburg, Florida, 33713, United States
-
Site Number - 1605
New York, New York, 10032, United States
-
Site Number - 1606
Houston, Texas, 77030, United States
-
Site Number - 1610
Charlotte, North Carolina, 28207, United States
-
Site Number - 1611
Nicholasville, Kentucky, 40356, United States
-
Site Number - 1613
Milwaukee, Wisconsin, 53226-3548, United States
-
Site Number - 1614
Portland, Oregon, 97239, United States
-
Site Number - 1617
Ormond Beach, Florida, 32174, United States
-
Site Number - 1620
Port Charlotte, Florida, 33952, United States
-
Site Number - 1621
New Haven, Connecticut, 06519, United States
-
Site Number - 1623
Philadelphia, Pennsylvania, 19104, United States
-
Site Number - 1624
Philadelphia, Pennsylvania, 19104, United States
-
Site Number - 1625
Aurora, Colorado, 80045, United States
-
Site Number - 1628
San Antonio, Texas, 78229, United States
-
Site Number - 1629
Orlando, Florida, 32806-5411, United States
-
Site Number - 1632
Seattle, Washington, 98195-0001, United States
-
Site Number - 1633
Rockledge, Florida, 32955, United States
-
Site Number - 1634
Los Angeles, California, 90033-5330, United States
-
Site Number - 2600
Edmonton, Alberta, T6J 1M3, Canada
-
Site Number - 2603
Vancouver, British Columbia, V6Z 1Y6, Canada
-
Site Number - 3201
Katowice, Silesian Voivodeship, 40-123, Poland
-
Site Number - 3202
Mazurki, Lublin Voivodeship, 20-093, Poland
-
Site Number - 3203
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
-
Site Number - 3205
Gdansk, Pomeranian Voivodeship, 80-803, Poland
-
Site Number - 3206
Lublin, Lublin Voivodeship, 20-701, Poland
-
Site Number - 3207
Poznan, Greater Poland Voivodeship, 61-731, Poland
-
Site Number - 3208
Krakow, Lesser Poland Voivodeship, 30-688, Poland
-
Site Number - 3209
Krakow, Lesser Poland Voivodeship, 31-202, Poland
-
Site Number - 3210
Lublin, Lublin Voivodeship, 20-064, Poland
-
Site Number - 3211
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-065, Poland
-
Site Number - 3241
Turku, Southwest Finland, 20520, Finland
-
Site Number - 3700
San Sebastián, Gipuzkoa, 20014, Spain
-
Site Number - 3701
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Site Number - 3703
Barcelona, 08025, Spain
-
Site Number - 3704
Sant Cugat del Vallès, Barcelona, 08190, Spain
-
Site Number - 3741
Lisbon, 1300-344, Portugal
-
Site Number - 3742
Senhora da Hora, Porto District, 4464-513, Portugal
-
Site Number - 3743
Almada, Setúbal District, 2805-267, Portugal
-
Site Number - 3744
Porto, 4099-001, Portugal
-
Site Number - 3745
Vila Nova de Gaia, Porto District, 4434-502, Portugal
-
Site Number - 4680
Leuven, Vlaams Brabant, 03000, Belgium
-
Site Number - 4681
Ghent, Oost-Vlaanderen, 09000, Belgium
-
Site Number - 4740
Copenhagen, 02100, Denmark
-
Site Number - 4891
Gothenburg, Västra Götaland County, 413 45, Sweden
-
Site Number - 6300
Pavia, 27100, Italy
-
Site Number - 6301
Bergamo, Lombardy, 24127, Italy
-
Site Number - 6302
Gussago, Brescia, 25084, Italy
-
Site Number - 6303
Pisa, Tuscany, 56126, Italy
-
Site Number - 6305
Bologna, Emilia-Romagna, 40139, Italy
-
Site Number - 6306
Rome, Lazio, 00189, Italy
-
Site Number - 6307
Milan, Lombardy, 20132, Italy
-
Site Number - 6308
Siena, Tuscany, 53100, Italy
-
Site Number - 6309
Rome, Lazio, 00133, Italy
-
Site Number - 6341
Pátrai, Achaïa, 265 04, Greece
-
Site Number - 6342
Heraklion, Irakleio, 715 00, Greece
-
Site Number - 6343
Alexandroupoli, Evros, 68100, Greece
-
Site Number - 6344
Athens, Attica, 115 25, Greece
-
Site Number - 6345
Athens, Attica, 115 28, Greece
-
Site Number - 6346
Ioannina, 455 00, Greece
-
Site Number - 6347
Larissa, 41110, Greece
-
Site Number - 6491
Oslo, 00424, Norway
-
Site Number - 6702
Leipzig, Saxony, 04103, Germany
-
Site Number - 6705
Bochum, North Rhine-Westphalia, 44791, Germany
-
Site Number - 6706
Berlin, 10117, Germany
-
Site Number - 7400
Manchester, M6 8HD, United Kingdom
-
Site Number - 7401
Sheffield, South Yorkshire, S10 2JF, United Kingdom
-
Site Number - 7402
Southampton, Hampshire, SO16 6YD, United Kingdom
-
Site Number - 7403
Preston, Lancashire, PR2 9HT, United Kingdom
-
Site Number - 7404
Glasgow, Lanarkshire, G51 4TF, United Kingdom
-
Site Number - 7405
Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom
-
Site Number - 7750
Buenos Aires, C1199ABB, Argentina
-
Site Number - 7751
Rosario, Santa Fe Province, S2000DTP, Argentina
-
Site Number - 7752
San Miguel de Tucumán, Tucumán Province, T4000AXL, Argentina
-
Site Number - 7753
Rosario, Santa Fe Province, S2000BZL, Argentina
-
Site Number - 8401
Târgu Mureş, Mureș County, 540136, Romania
-
Site Number - 8403
Timișoara, Timiș County, 300736, Romania
-
Site Number - 8406
Bucharest, Bucharest, 41914, Romania
-
Site Number - 8500
Niš, 18000, Serbia
-
Site Number - 8501
Belgrade, 11000, Serbia
-
Site Number - 8502
Belgrade, 11000, Serbia
-
Site Number - 8503
Novi Sad, 21000, Serbia
-
Site Number - 8600
Liptovský Mikuláš, 031 23, Slovakia
-
Site Number - 8601
Martin, 036 01, Slovakia
-
Site Number - 8602
Trnava, 91775, Slovakia
-
Site Number - 8603
Prešov, 081 81, Slovakia
-
Site Number - 9100
Ribeirão Preto, São Paulo, 14048-900, Brazil
-
Site Number - 9101
Curitiba, Paraná, 81210-310, Brazil
-
Site Number - 9103
Brasília, Federal District, 70200-730, Brazil
-
Site Number - 9105
São Paulo, 01409-000, Brazil
-
Site Number - 9110
Sofia, Sofia-Grad, 01606, Bulgaria
-
Site Number - 9111
Sofia, Sofia-Grad, 01527, Bulgaria
-
Site Number - 9112
Pleven, 05800, Bulgaria
-
Site Number - 9900
Seoul, 06351, South Korea
-
Site Number - 9901
Seoul, 02841, South Korea
-
Site Number -1601
Austin, Texas, 78759, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test track nerve damage? a study investigates NT-3 levels in neuropathy.
- New drug mimics natural protein to calm overactive immune system in nerve disease
- Shocking muscles to move: new exercise hope for nerve disease patients
- Could a stem cell transplant stop the immune system from attacking the brain?
- Engineered immune cells take on multiple sclerosis and other nerve diseases
- New drug IMVT-1402 aims to stop CIDP relapses in Mid-Stage trial